Revised, more industry-friendly PLI scheme for bulk drugs on the cards

Industry says move will mean lower spends and reduced dependence on China

The production-linked incentive (PLI) scheme to boost local manufacturing of bulk drugs or ingredients to make medicines may be revised to make it more industry-friendly. The technical committee under the Department of Pharmaceuticals has submitted its recommendations this week, sources said. 

If the recommendations are accepted, there may be an interim scheme that would allow manufacturers to claim some incentives when they produce and supply over 40 identified bulk drugs. 

Mahesh Doshi, national president of the Indian Drug Manufacturers’ Association (IDMA), said that if a certain assurance is given to local bulk drug players on at least 10-15 of the identified 41